Why should the Alzheimer's Organization care what's being said about a specific company or their drug?
Since they completed enrollment in late September, Phase 2 Part B final results won't be available until Sept. 2016.
From their PR release September 28th:
"PART B is an open-label extension for an additional 52 weeks, with daily oral dosing so as to establish a longer drug effect."
Isn't the goal of a phase III trial to prove taking the drug results in cognitive improvement?
So if cognitive improvement was already proven, like you stated, why not just file for FDA approval?
If this weekend made it clear that Anavex 2-73 will get FDA approval then the stock should be trading much higher today.
Too early for such an assertion.
Which professional and unaffiliated scientists are saying that?
Hopefully you're not talking about the PR statements.
It was not useless, the trial was designed for safety and dosage.
Problem is they're implying efficacy, which can't be determined at this stage.
No, his statement implied that the rest of their pipeline was valuable.
I just asked which of those other pipeline drugs does he thinks the market is undervaluing.
Maybe you can answer.
RVT-101 has been through tested thousands of patients, Anavex 2-73 on 32. I think that and the fact that AXON's CEO is a good snake oil salesman are the reasons for the MC difference.